A deep dive into the implications of the Replimune CRL that surprised insiders and investors, the role of new leadership at ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit ...

Complete Response Letters recently issued by the FDA signal heightened scrutiny of trial design and reinforce the agency’s shifting regulatory expectations for sponsors and CROs.

Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the ...

J.P. Morgan analyst Anupam Rama maintained a Buy rating on AnaptysBio today and set a price target of $80.00. The company’s shares opened today at $28.15. Take advantage of TipRanks Premium at 50% off ...

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...